



08-14-02

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE1621  
HJL  
8/21/02  
RECEIVED  
AUG 19 2002  
TECH CENTER 1600/2900SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTDocket Number:  
1662/54903

Application Number 10/000,428	Filing Date Nov. 30, 2001	Examiner To be Assigned	Art Unit 1621
Invention Title CRYSTALLINE VENLAFAZINE BASE AND NOVEL POLYMORPHS OF VENLAFAZINE HYDROCHLORIDE, PROCESSES FOR PREPARING THEREOF	Inventor(s) DOLITZKY et al.		

Address to:  
Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner for Patents, Washington, D.C. 20231,  
on

Date 8/12/02

Signature athene Edmund  
KENYON & KENYON

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the following reference to the attention of the Examiner. This reference is listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to-be-material-to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 8/12/02By: Siu K. Lo  
Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)



**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT**

ATTY. DOCKET NO.  
**01662/54903**

SERIAL NO.  
**10/000,428**

APPLICANT  
**DOLITZKY et al.**

FILING DATE  
**November 30, 2001**

GROUP  
**1621**

**RECEIVED**  
AUG 19 2002  
TECH CENTER 1600/29m

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB-CLASS	FILING DATE*
	4,611,078	Sept. 9, 1986	Husbands et al.			

\* - if pertinent

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/32555	June 8, 2000	PCT			N/A	

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	
	J.P. Yardley, et al., 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity, Journal of Medicinal Chemistry, 1990, 33, pp. 2899-2905	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	